# Study of ACE-536 in Healthy Postmenopausal Women

> **NCT01432717** · PHASE1 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 40 (actual)

## Conditions studied

- Anemia

## Interventions

- **BIOLOGICAL:** ACE-536
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01432717
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01432717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01432717, "Study of ACE-536 in Healthy Postmenopausal Women". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01432717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*